Top Markets
Coin of the day
Edesa Biotech, Inc. Edesa Biotech, Inc.

Edesa Biotech, Inc.

EDSA
Rank in Stocks #25796
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Share Price
$4.80
Market Cap
$46.24M
Change (1 day)
-16.52%
Change (1 year)
103.39%
Country
CA
Trade Edesa Biotech, Inc. (EDSA)

Category

Earnings for Edesa Biotech, Inc. (EDSA)
Earnings in 2026 TTM: 0
According to Edesa Biotech, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Edesa Biotech, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US